0001818382-24-000101.txt : 20240613
0001818382-24-000101.hdr.sgml : 20240613
20240613164833
ACCESSION NUMBER: 0001818382-24-000101
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240611
FILED AS OF DATE: 20240613
DATE AS OF CHANGE: 20240613
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Niklason Laura E
CENTRAL INDEX KEY: 0001878075
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39532
FILM NUMBER: 241041909
MAIL ADDRESS:
STREET 1: 35 WILSHIRE ROAD
CITY: GREENWICH
STATE: CT
ZIP: 06831
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Humacyte, Inc.
CENTRAL INDEX KEY: 0001818382
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 851763759
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919-313-9633
MAIL ADDRESS:
STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54
CITY: DURHAM
STATE: NC
ZIP: 27713
FORMER COMPANY:
FORMER CONFORMED NAME: Alpha Healthcare Acquisition Corp.
DATE OF NAME CHANGE: 20200716
4
1
wk-form4_1718311705.xml
FORM 4
X0508
4
2024-06-11
0
0001818382
Humacyte, Inc.
HUMA
0001878075
Niklason Laura E
2525 EAST NORTH CAROLINA HIGHWAY 54
DURHAM
NC
27713
1
1
0
0
President, CEO and Director
0
Common Stock
2024-06-11
4
S
0
282000
7.0922
D
4907288
I
By Ayabudge LLC
Common Stock
2024-06-11
4
S
0
76630
7.02
D
4830658
I
By Ayabudge LLC
Common Stock
2024-06-12
4
S
0
271518
7.30
D
4559140
I
By Ayabudge LLC
Common Stock
240832
D
Common Stock
1148240
I
By The Niklason Living Trust
Common Stock
510161
I
By spouse
Shares were sold in a private transaction to a trust controlled by family members of the Reporting Person. Said family members do not share the same household as the Reporting Person.
The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.00 to $7.115. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $7.25 to $7.545. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
2024-06-13